Findings from two studies highlight the potential for CagriSema, a dual agonist that targets both glucose regulation and appetite control, to improve weight loss in patients with and without type 2 diabetes who have overweight or obesity. The studies were presented as a late-breaking symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in the New England Journal of Medicine.
Nearly 90% of U.S. adults who have diabetes also have overweight or obesity, underscoring the close link between excess weight and the development or progression of type 2 diabetes. While treatment options for obesity and type 2 diabetes have progressed with glucagon-like peptide-1 (GLP-1) receptor agonists, there is an ongoing need for therapies that can address weight and glucose management together. CagriSema, the dual agonist studied in REDEFINE 1 and 2, is designed to meet this need by targeting two key pathways: appetite regulation and blood glucose management.
REDEFINE 1 and 2 are 68-week phase 3 studies evaluating the safety and effectiveness of CagriSema, a once-weekly combination of weight-loss medications semaglutide and cagrilintide. REDEFINE 1 enrolled 3,400 adults without diabetes but with at least one weight-related health condition, such as high blood pressure or heart disease. Participants were randomized to receive CagriSema, semaglutide, cagrilintide, or placebo. REDEFINE 2 enrolled 1,200 adults with type 2 diabetes, who received either CagriSema or placebo.
Both REDEFINE 1 and 2 met their goals, demonstrating improved weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight with CagriSema at week 68, compared to 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo. When accounting for full treatment adherence, weight loss with CagriSema rose to 22.7%, with 40.4% of participants achieving at least 25% weight loss. In REDEFINE 2, participants lost an average of 13.7% at week 68, compared to 3.4% with placebo. When considering the results of all study participants adhered to treatment, weight loss with CagriSema rose to 15.7%, compared to 3.1% with placebo.
